MR引导放疗用于淋巴结阳性非小细胞肺癌且肺储备严重受限患者:一份提出高危患者管理新临床路径的报告
本技术报告描述一例淋巴结阳性IIB期非小细胞肺癌且肺功能与肺储备严重受损的患者,在前瞻性观察研究中接受MR引导的大分割放疗,总剂量48.0 Gy/16次每日照射,耐受良好,无相关毒性,放疗后3个月首次随访影像显示部分缓解,并提出高危患者管理的临床路径。
要点
- 患者肺功能严重受损:TLC 8.78L/132%预计值,RV 6.35L/271%预计值,VC最大2.43L/58%预计值,FEV1 1.19L/38%预计值,DLCO-SB经血红蛋白校正2.76 mmol/min/kPa/30%预计值。
- 在MRIdian系统上实施中等大分割MRgRT,总剂量48.0 Gy/16次每日照射,放疗耐受良好,无相关毒性。
- 放疗后3个月首次随访影像显示部分缓解;该病例为前瞻性观察研究中首例接受在线MR引导加速大分割放疗的原发淋巴结阳性NSCLC患者。
核心结论
- 本技术报告描述了前瞻性观察研究中首例接受该相对新技术治疗IIB(N1)/III期疾病的患者,并提出高危患者管理的临床路径。
研究设计与样本
- 技术报告,分析一例淋巴结阳性IIB期NSCLC且肺功能与肺储备严重受损患者在前瞻性观察研究中的肿瘤运动和呼吸曲线。
主要发现
- 放疗耐受良好,无相关毒性。
- 放疗后3个月首次随访影像显示部分缓解。
- 该病例特点为患者肺功能严重受损,且为原发淋巴结阳性NSCLC首例在线MR引导加速大分割放疗。
关键数值与推荐
- 在MRIdian系统(Viewray Inc, Oakwood, USA)上实施中等大分割MRgRT,总剂量48.0 Gy/16次每日照射。
- 患者肺功能:TLC 8.78L/132%预计值,RV 6.35L/271%预计值,VC最大2.43L/58%预计值,FEV1 1.19L/38%预计值,DLCO-SB经血红蛋白校正2.76 mmol/min/kPa/30%预计值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Online MR-guided radiotherapy (MRgRT) is a relatively novel advancement in the field of radiation oncology, ensuring superior soft-tissue visualisation, allowing for online plan adaptation to anatomical and functional interfractional changes and improved motion management. Platinum-based chemoradiation followed by durvalumab is the recommended treatment for stage IIB(N1)/III NSCLC. However, this is only the case for patients with favourable risk factors and sufficient pulmonary function and reserve. METHODS: Herein, we present a technical report on tumour motion and breathing curve analyses of the first patient with node-positive stage IIB NSCLC and severely compromised pulmonary function and reserve [total lung capacity (TLC) 8.78L/132% predicted, residual volume (RV) 6.35L/271% predicted, vital capacity (VC) max 2.43L/58% predicted, FEV1 1.19L/38% predicted, DLCO-SB corrected for hemoglobin 2.76 mmol/min/kPa/30% predicted] treated in a prospective observational study with moderately hypofractionated MRgRT to a total dose of 48.0 Gy/16 daily fractions on the MRIdian system (Viewray Inc, Oakwood, USA). RESULTS: Radiotherapy was well tolerated with no relevant toxicity. First follow-up imaging at 3 months post-radiotherapy showed a partial remission. The distinctive features of this case are the patient's severely compromised pulmonary function and the first online MR-guided accelerated hypofractionated radiotherapy treatment for primary node-positive NSCLC. CONCLUSIONS: This technical report describes the first patient treated in a prospective observational study evaluating the feasibility of this relatively novel technology in stage IIB(N1)/III disease, proposing a clinical pathway for the management of high-risk patients.
引用
- Eze C, Lombardo E, Nierer L, et al. MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients. Radiat Oncol. 2022. PMID: 35209922. doi:10.1186/s13014-022-02011-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。